Physician profile
Eric James Faile
NPI 1942247382
$15,075.31
in general payments reported to CMS, 2019-2025
64 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,143 · 2020: $984 · 2021: $2,547 · 2022: $2,405 · 2023: $2,843 · 2024: $2,332 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,995.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,082.69 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $1,875.47 | 2019-2025 | |
| Pfizer INC. | $1,147.44 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,047.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $995.09 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $613.62 | 2019-2022 | |
| Amgen INC. | $533.37 | 2019-2024 | Otezla, Repatha, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $533.31 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $509.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $491.64 | 2019-2025 | Rexulti, Nuedexta |
| Glaxosmithkline, LLC. | $411.14 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $380.74 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.25 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $346.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $325.39 | 2019-2023 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Faile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.